BERKELEY, Calif.--(BUSINESS WIRE)--Newomics Inc., a biotechnology company developing and commercializing mass spectrometry solutions, today announced that it has established a North America Sales Team, and it is launching a new product to enhance the existing mass spectrometry workflows.
Newomics continues its dedication to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The MnESI platform (M3 multinozzle emitter + MnESI source), launched in November 2020 to enhance the capabilities of Thermo Fisher Scientific and Bruker mass spectrometers, is receiving acceptance in the market. To enhance the MnESI platform, Newomics is releasing the Newomics Flow Splitting Kit, which converts a conventional analytical flow rate to a wide range of microflow rates (1-25 microliter per min). Typically, scientists would have had to purchase a new LC instrument to do this, costing upwards of $150k. But the Newomics Flow Splitting Kit is compatible with many high flow LC systems widely found in research labs. The advantage is that it allows scientists to analyze samples without changing their current high flow LC and column setups. Pairing the flow splitting kit with the MnESI source and M3 emitter outperforms routine analytical flow mass spectrometry and delivers higher sensitivity. In addition, using a very small fraction of sample material significantly reduces sample contamination to the mass spectrometers and thus improves workflow robustness.
The commercial growth of Newomics also continues with the completion of the first phase of our world-wide sales, customer support, and distribution network. In North America, the Newomics direct sales team is in place to grow our business and support our largest customers including Regeneron, Genentech, and the CDC. Newomics has appointed distributors in Europe, Japan, China, Singapore, and Taiwan to open those markets with our advanced M3 emitter and MnESI platform and now the new Newomics Flow Splitting Kits.
Daojing Wang, PhD., Newomics founder and CEO, says he is especially pleased with how customers have embraced the MnESI platform. Dr. Wang continues: “We developed the flow splitting kits in response to the voices of our customers. With the completion of the first phase of our world-wide sales, customer support and distribution network, we are ready to fulfill customer needs and provide support to address the challenges in their mass spectrometry workflows.”
Newomics Inc. is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. The company’s products, which enhance the performance of mass spectrometry instruments, can be ordered at www.newomics.com.